• News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
    • Scientific Presentations
  • Investors
    • Overview
    • Rights Issue / Företrädesemission 2025
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Board and Management
    • The Share
    • Financial Reports
      • Financial Reports - English
      • Financial Reports – Swedish
      • Financial Calendar
    • Corporate Governance
    • General Meetings
    • IR Contact
  • Rights Issue 2025
  • Career
  • Contact
logo
  • News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
    • Scientific Presentations
  • Investors
    • Overview
    • Rights Issue / Företrädesemission 2025
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Board and Management
    • The Share
    • Financial Reports
      • Financial Reports - English
      • Financial Reports – Swedish
      • Financial Calendar
    • Corporate Governance
    • General Meetings
    • IR Contact
  • Rights Issue 2025
  • Career
  • Contact
Home / Investors / The Share
  • Overview
  • Rights Issue / Företrädesemission 2025
  • Press Releases
    • English
    • Swedish
    • Subscribe
  • Presentations
  • Board and Management
  • The Share
  • Financial Reports
    • Financial Reports - English
    • Financial Reports – Swedish
    • Financial Calendar
  • Corporate Governance
  • General Meetings
  • IR Contact

The Share

 

Share Information

The Alzinova share is traded on Nasdaq First North Growth Market. The company has a registered share capital of 23,450,515.98 SEK, divided on 89,165,460 shares. The quota value is 0.263 SEK/share. Shares are registered by Euroclear Sweden AB.

Name: Alzinova AB
Ticker: ALZ
ISIN code: SE0007413455
LEI-code: 549300K3IMVT20EK2S13

Share price and trading can be followed on Nasdaq First North Growth Market 

Liquidity provider Mangold Fondkommission acts as liquidity provider for the Alzinova share. The purpose is to promote liquidity in the trading of the share. The agreement and the trading of the liquidity provider started July 1, 2024.

Largest Shareholders

As per Euroclear, 31 March 2025

Largest Shareholders

Redeye Analyst Coverage

Additional Analyst Coverage

Carnegie Investment Bank AB
Ludvig Svensson – Commissioned Research
Phone: +46 704 96 25 35
E-mail: ludvig.svensson@carnegie.se

Company site at Carnegie Investment Bank

Analysis 8 April 2025 View pdf

Analysis 19 February 2025 View pdf

Analysis 27 January 2025 View pdf

Analysis 15 May 2024 (Swedish). View pdf

Analysis 29 February 2024 (Swedish). View pdf

Analysis 21 November 2023 (Swedish). View pdf 

Analysis 21 November 2023 (English). View pdf 

 

Additional Equity Research by Carlsquare

Analysis in Swedish 

Certified Adviser

Alzinova AB has contracted Mangold Fondkommission AB as Certified Adviser on Nasdaq First North Growth Market. As a Certified Adviser, Mangold guide and monitor the company’s compliance on Nasdaq First North Growth Market.

Contact information to Mangold Fondkommission AB:
Info@mangold.se
phone +46 (0)8-503 01 550

Rights issues & Share capital development

Previous Share Issuances

Share Capital Development

  • News
  • Our Company
  • Patients & Families
  • R & D
  • Investors
  • Contact

Alzinova AB, Gemenskapens gata 9,  SE-431 53 Mölndal
info@alzinova.com

Follow us on

follow us on linkedin